RxDoctor Payments Data

Renessa Gerhardt, MD

Family Medicine · Athens, TXNPI 1790216224

Payments from drug & device makers

$1,043in general payments, 2019–2025

Across 48 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$383
  • AbbVie$140
  • AstraZeneca$136
  • Pfizer$105
  • Amgen$62
  • Boston Scientific$31
  • plus $185 from 9 others

What the payments were for

  • Food & beverage$1,043100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,043 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$119,865
Medicare patients
253
Services billed
2,896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin88$98,044
OzempicSemaglutide57$73,965
FarxigaDapagliflozin Propanediol33$21,516
EliquisApixaban23$21,126
Duloxetine Hcl248$5,973
VascepaIcosapent Ethyl13$4,131
Gabapentin225$3,046
Levothyroxine Sodium257$2,931
Atorvastatin Calcium358$2,820
Azelastine Hcl115$2,753
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,679
Dexlansoprazole DrDexlansoprazole13$2,460
Albuterol Sulfate HfaAlbuterol Sulfate70$2,122
Lisinopril299$2,045
Pantoprazole Sodium143$1,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$25$98,04488 claims
Novo NordiskOzempic$383$73,96557 claims
AstraZenecaFarxiga$136$21,51633 claims
PfizerEliquis$105$21,12623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Athens

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →